FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Flexible Regulatory Approaches for Cell/Gene Therapy CMC Info

FDA articulates a flexible regulatory approach to chemistry, manufacturing and controls for cell and gene therapies, a move the agency says is intende...

latest-news-card-1
Human Drugs

Orphan Status for Novita Pancreatic Cancer Drug

FDA grants Novita Pharmaceuticals an orphan drug designation for its experimental cancer drug NP-G2-044 for treating pancreatic cancer.

latest-news-card-1
Human Drugs

Pediatric Menkes Disease Drug Approved

FDA approves a Sentynl Therapeutics NDA for Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients.

latest-news-card-1
Human Drugs

Fast Track for Alessas Prostate Cancer Therapy

FDA grants Alessa Therapeutics a fast track designation for Enolen, an experimental localized prostate cancer therapy.

latest-news-card-1
Human Drugs

FDA Cites Aurobindo for Drug Supply Security Lapses

FDA cites Aurobindo Pharma USA for multiple failures to comply with federal drug supply chain security requirements, including delays in reporting sto...

latest-news-card-1
Medical Devices

AVID Medical Recalls Organ Recovery Bags

AVID Medical recalls (Class 1 device correction) certain organ recovery and medical convenience kits.

latest-news-card-1
Human Drugs

FDA Guide Outlines Expectations for Bayesian Trial Designs

A new FDA guidance details how drug developers can appropriately use Bayesian statistical methods in clinical trials intended to support approvals.

latest-news-card-1
Human Drugs

FDA Flags Deficiencies in Aquestives Anaphylm NDA

FDA tells Aquestive Therapeutics that deficiencies have been identified in the companys NDA for Anaphylm that currently preclude labeling and post-mar...

latest-news-card-1
Human Drugs

FDA Accepts Camurus NDA Resubmission for Acromegaly Drug

FDA accepts for review a Camurus NDA resubmission for Oclaiz (octreotide), a once-monthly treatment for acromegaly.

latest-news-card-1
Marketing

Cobenfy Ad Letter Signals Tight Limits on DTC Claims: Attorneys

A December FDA violation letter targeting a schizophrenia drug advertisement from Bristol Myers Squibbs Karuna Therapeutics unit underscores the agenc...